Skip to content
Lower risk Drug recall · FDA · Published February 4, 2026

Somerset Therapeutics Dexamethasone Injection Recall: Impurities May Cause Harm

Somerset Therapeutics recalls 10x10mL Dexamethasone Sodium Phosphate injection vials due to impurities detected during stability testing. These impurities could pose health risks if used beyond expiry.

🇺🇸 FDA recall #D-0398-2026DrugSomerset Therapeutics ›
Take action

Contact the company

Recalling firmSOMERSET THERAPEUTICS LLC300 Franklin Square Dr · Somerset, NJ 08873-4187
✎ GovInfoNow plain-language explainer

Somerset Therapeutics is recalling 10x10 mL Dexamethasone Sodium Phosphate injection vials because impurities were found during long-term stability testing. These impurities could potentially cause health risks if the medication is used after the expiry date. Read more at govinfonow.com/recall/31492-somerset-therapeutics-dexamethasone-injection-recall-impurities-may-cause-harm.

Source Summary by GovInfoNow · govinfonow.com/recall/31492-somerset-therapeutics-dexamethasone-injection-recall-impurities-may-cause-harm · Updated August 17, 2026 · FDA enforcement record: FDA #D-0398-2026

Cite this page

“Somerset Therapeutics Dexamethasone Injection Recall: Impurities May Cause Harm.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31492-somerset-therapeutics-dexamethasone-injection-recall-impurities-may-cause-harm. Based on FDA recall #D-0398-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0398-2026%22&limit=1).

The FDA announced on Feb. 4, 2026, that Somerset Therapeutics is recalling Dexamethasone Sodium Phosphate Injection due to failed impurity specifications. The recall affects 62,190 vials distributed nationwide.

How to tell if you have it

  • Brand: Somerset Therapeutics
  • Product: Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials
  • NDC carton: 70069-025-10
  • NDC vial: 70069-025-01
  • Lot #: A240421
  • Expiration: 07/31/2026

The hazard

The product contains out-of-specification impurities, specifically Dexamethasone Sodium Phosphate EP impurity G and dexamethasone formate, which were observed during long-term stability testing at the 24-month expiry. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Somerset Therapeutics has issued four other recalls since June 4, 2020, including a Nov. 26, 2025, recall for subpotent Cisatracurium Besylate Injection and a Dec. 16, 2024, recall for Atropine Sulfate Ophthalmic Solution. Other recent recalls of similar products include Sun Pharmaceutical's Dec. 30, 2025, Fluocinolone Acetonide Solution recall for impurity risk and Sagent's May 4, 2026, Busulfan Injection recall for failed impurities.

How to tell if you have this one

Check for the product name 'Dexamethasone Sodium Phosphate Injection, USP, 100 mg/10 mL (10 mg/mL), 10x10 mL Multiple Dose Vials' with NDC carton number 70069-025-10 and vial number 70069-025-01. The lot number is A240421 with an expiration date of 07/31/2026.

  • Brand
    Somerset Therapeutics
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Identify the NDC carton number 70069-025-10 and vial number 70069-025-01 on the packaging.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 49 days after the firm started it.

1. Firm started the recall: Feb 4, 202612. FDA classified it Class II: Mar 18, 202623. Published in FDA’s Enforcement Report: Mar 25, 202632026
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0398-2026 (February 4, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0398-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA